LIV-1 Antibody-Drug Conjugate: A Novel Therapeutic Agent for Breast Cancer

被引：0
|
作者：
Smith, L. M. [1 ]
Sussman, D. [1 ]
Nesterova, A. [1 ]
Westendorf, L. [1 ]
Duniho, S. [1 ]
Anderson, M. [1 ]
Mbow, B. [1 ]
Gregoire, A. [1 ]
Hunter, J. [1 ]
Whiting, N. [1 ]
Law, C. L. [1 ]
Benjamin, D. R. [1 ]
机构：
[1] Seattle Genet Inc, Bothell, WA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-16
引用
收藏
页数：1
相关论文
共 50 条
  • [1] LIV-1 antibody-drug conjugate: A novel therapeutic agent for breast and prostate cancer
    Sussman, Django
    Nesterova, Albina
    Westendorf, Lori
    Duniho, Steven
    Anderson, Martha
    Mbow, Brianna
    Gregoire, Ashley
    Hunter, Joshua H.
    Whiting, Nancy
    Corey, Eva
    Vessella, Robert L.
    Benjamin, Dennis R.
    Smith, Leia M.
    CANCER RESEARCH, 2011, 71
  • [2] SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
    Sussman, Django
    Smith, Leia M.
    Anderson, Martha E.
    Duniho, Steve
    Hunter, Joshua H.
    Kostner, Heather
    Miyamoto, Jamie B.
    Nesterova, Albina
    Westendorf, Lori
    Van Epps, Heather A.
    Whiting, Nancy
    Benjamin, Dennis R.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 2991 - 3000
  • [3] SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer
    Forero, Andres
    Burris, Howard, III
    LoRusso, Patricia
    Specht, Jennifer
    Miller, Kathy
    Mita, Monica
    Liu, Minetta C.
    Modi, Shanu
    Pusztai, Lajos
    Sussman, Django
    Kostic, Ana
    CANCER RESEARCH, 2015, 75
  • [4] SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
    Sussman, Django
    Smith, Leia M.
    Anderson, Martha E.
    Duniho, Steve
    Hunter, Joshua H.
    Kostner, Heather
    Miyamoto, Jamie B.
    Nesterova, Albina
    Westendorf, Lori
    Van Epps, Heather A.
    Whiting, Nancy
    Benjamin, Dennis R.
    CANCER RESEARCH, 2013, 73 (08)
  • [5] SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1-positive breast cancer.
    Kostic, Ana
    Anderson, Martha
    Duniho, Steven
    Miyamoto, Jamie
    Nesterova, Albina
    Sussman, Django
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Anti-human LIV-1 antibody drug conjugate for treatment of metastatic prostate cancer
    Zhao, Xiaobei
    Chen, Gang
    CANCER RESEARCH, 2023, 83 (11)
  • [7] CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer
    Shiomi, Mayu
    Matsuzaki, Shinya
    Serada, Satoshi
    Matsuo, Koji
    Mizuta-Odani, Chihiro
    Jitsumori, Mariko
    Nakae, Ruriko
    Matsuzaki, Satoko
    Nakagawa, Satoshi
    Hiramatsu, Kosuke
    Miyoshi, Ai
    Kobayashi, Eiji
    Kimura, Toshihiro
    Ueda, Yutaka
    Yoshino, Kiyoshi
    Naka, Tetsuji
    Kimura, Tadashi
    CANCER SCIENCE, 2021, 112 (09) : 3655 - 3668
  • [8] Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
    Forero, A.
    Burris, H., III
    Mita, M.
    Specht, J.
    Weise, A.
    Liu, M. C.
    Modi, S.
    Pusztai, L.
    Kostic, A.
    Yang, J.
    Li, M.
    Hengel, S.
    Miller, K.
    CANCER RESEARCH, 2016, 76
  • [9] Zinc and Cancer: Implications for LIV-1 in Breast Cancer
    Grattan, Bruce J.
    Freake, Hedley C.
    NUTRIENTS, 2012, 4 (07): : 648 - 675
  • [10] Antibody-drug conjugate against breast cancer approved
    不详
    BIOENGINEERED, 2013, 4 (03) : 121 - 121
12345